UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~August~~ 14September 8, 2025

GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Nevada	001-31791	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock $0.001par value per share	GALT	The Nasdaq Stock Market

~~SECTION~~Item 27.01 –Regulation ~~FINANCIAL~~FD ~~INFORMATION~~Disclosure.

~~Item~~On 2September 8, 2025, Galectin Therapeutics Inc.02 ~~Results~~(the “Company”) posted to its website an updated Corporate Presentation attached hereto as Exhibit 99.1. A copy of ~~Operations~~the presentation is furnished herewith as Exhibit 99.1 and ~~Financial~~incorporated ~~Condition~~herein by reference.

~~On August~~In ~~14,~~accordance ~~2025,~~with ~~Galectin~~General ~~Therapeutics~~Instruction ~~Inc~~B.2 ~~(“Galectin~~of ~~Therapeutics”)~~Form ~~issued~~8-K, athe ~~press~~information ~~release announcing~~furnished ~~its~~under ~~results~~this Item 7.01 of ~~operations~~this Current Report on Form 8-K and ~~financial~~the exhibits ~~condition~~attached ashereto ofare deemed to be “furnished” and shall not be deemed “filed” for the ~~six~~purpose ~~months~~of ~~ended~~Section ~~June~~18 ~~30,~~of ~~2025~~the Exchange Act, ~~and~~or ~~provided~~otherwise asubject ~~business~~to ~~update.~~the ~~Galectin~~liabilities ~~hereby~~of ~~incorporates~~that bysection, ~~reference~~nor ~~herein~~shall ~~the~~such information ~~set~~and ~~forth~~exhibits inbe ~~its~~deemed incorporated ~~press~~by ~~release~~reference ~~dated~~into ~~August 14,~~any ~~2025~~filing (under the ~~“Press~~Securities ~~Release”)~~Act of 1933, aas ~~copy~~amended, ofor ~~which~~the isSecurities ~~attached~~Exchange ~~hereto~~Act asof ~~Exhibit~~1934, 99as amended.1.

~~Except~~This ~~for~~Current ~~the~~Report ~~historical~~on ~~information~~Form ~~contained~~8-K inand ~~this~~Exhibit ~~report,~~99.1 ~~the~~hereto ~~statements~~contain ~~made by Galectin Therapeutics are~~ forward-looking statements ~~that~~within ~~involve risks and uncertainties. All such statements are subject to~~ the ~~safe~~meaning ~~harbor~~of ~~created by~~ the ~~Private~~federal ~~Securities~~securities ~~Litigation Reform Act of 1995~~laws. These ~~Galectin~~forward-looking ~~Therapeutics’~~statements ~~future~~are ~~financial~~based ~~performance~~on ~~could~~current ~~differ significantly from the~~ expectations ~~of management~~ and ~~from~~are ~~results~~not ~~expressed~~guarantees orof ~~implied~~future inperformance. Further, the ~~Press Release. Forward~~forward-looking statements ~~in the Press Release~~ are subject to ~~certain~~the ~~risks~~limitations ~~and~~listed ~~uncertainties described~~ in ~~the~~Exhibit ~~Press Release~~99.1 ~~For~~and ~~further~~in ~~information~~the on other ~~risk~~reports ~~factors,~~of ~~please refer to~~ the ~~“Risk~~Company filed ~~Factors”~~with ~~contained in Galectin Therapeutics’ Annual Report on Form 10-K for~~ the ~~fiscal~~Securities ~~year~~and ~~ended~~Exchange ~~December 31~~Commission, ~~2024,~~including asthat ~~filed~~actual ~~with~~events ~~the~~or ~~Securities~~results ~~and~~may ~~Exchange~~differ ~~Commission,~~materially ~~and~~from ~~its~~those ~~subsequent~~in ~~filings with~~ the ~~SEC~~forward-looking statements.

The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
Exhibit No.		Exhibit Description
99.1		~~Press~~Galectin ~~Release~~Therapeutic ~~dated~~Inc. ~~August~~Corporate 14Presentation, updated September 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Galectin Therapeutics Inc.
Date: August 14, 2025	By:	/s/ Jack W. Callicutt
Date: September 8, 2025	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Chief Financial Officer

- 3 -

Filing Compare · GALECTIN THERAPEUTICS INC